Kenneth Pittman
Long only, value, biotech, healthcare

Cytokinetics Has Potential Positive Catalysts, But Concerning Technical Picture

Quick Background:

In May, I wrote an article on Cytokinetics (NASDAQ:CYTK) detailing why it still shows value potential despite setbacks. I have now been following Cytokinetics for over a year and a half, monitoring both clinical developments and the technical picture. I am a physician (bo...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.